伊藤 翔太

BACKGROUND: Radial extracorporeal shock wave therapy (rESWT) improves lower-limb spasticity after stroke. However, the efficacy of rESWT in individuals with hemiparetic stroke in the subacute phase, in whom neural components of spasticity are thought to predominate, has not been sufficiently investigated. In addition, the effects of different numbers of stimulations on the magnitude and duration of spasticity improvement remain unclear. OBJECTIVE: We aim to explore the effects of different numbers of stimulations during a single rESWT session on lower-limb spasticity in individuals with subacute stroke and assess the feasibility and safety of the evaluation and treatment procedures for future large-scale trials. METHODS: This single-center, open-label pilot randomized controlled trial will enroll 24 individuals with subacute stroke and spasticity who will be randomly assigned to either the rESWT 3000- or 6000-stimulation group for 1 treatment at the triceps surae muscle, with stimulation applied at 3 locations: the medial and lateral heads of the gastrocnemius muscle and the triceps surae muscle-Achilles tendon junction. The stimulation intensity will be the maximum intensity tolerated by the individual (≤3.0 bar), with a 10-Hz fixed frequency. Evaluations will be performed the day before treatment; immediately before and after completion of treatment; at 1 and 8 hours after treatment; and at 1, 2, 3, 5, 7, and 14 days after treatment. The primary clinical outcome is the intergroup difference in the Modified Ashworth Scale score of the triceps surae immediately after completion of treatment. Secondary clinical outcomes include intergroup differences in Modified Ashworth Scale scores at 1 and 8 hours and on days 1, 2, 3, 5, 7, and 14 after treatment, as well as intragroup differences from baseline to each evaluation point. Additional measures include the range of motion, angle of catch, tendon reflexes, and clonus scores. Feasibility will be assessed using the recruitment, enrollment, adherence, and retention rates. Safety will be assessed by recording the occurrence of serious and treatment-related adverse events. RESULTS: This study was approved by the Fujita Health University Institutional Review Board on September 26, 2024 (CR24-033). Participant enrollment commenced on November 19, 2024. By November 25, 2025, a total of 14 participants had been enrolled. Data analysis has not commenced, and the results will be reported in a separate article in 2026. CONCLUSIONS: This exploratory dose comparison pilot study is designed to explore whether the number of stimulations delivered during a single rESWT session influences the extent of short-term improvement in spasticity following subacute hemiparetic stroke and obtain preliminary clinical outcomes and feasibility and safety data for future large-scale trials. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs042240098; https://jrct.mhlw.go.jp/en-latest-detail/jRCTs042240098. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/88443.

Abstract We aimed to evaluate the applicability of a newly developed joint angle measurement system comprising six-axis inertial measurement unit sensors and tablet-based application for estimating joint angles from angular velocity and acceleration data. The application calculated orientation angles from single sensor data, with relative angles calculated using multiple sensors. In experiment 1, validity and reliability were examined using a test device. In experiment 2, static angles of five joints were calculated in four healthy participants using attached sensors and compared with universal goniometer values. In experiment 3, usability and satisfaction were evaluated using the System Usability Scale (SUS) and Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST)-like scale. In experiment 1, mean difference and root mean squared error (RMSE) between the developed system and test device were < 0.2° and < 1.0°, respectively, across all axes. In experiment 2, when data from all joints were pooled, mean difference and RMSE were 0.2° and 3.8°, respectively. Mean difference and RMSE across each joint were < 5°, indicating the system is comparable to universal goniometer. In experiment 3, median SUS and QUEST-like scores were 73.8 and 4.0, respectively, indicating good usability and satisfaction. The developed system has high accuracy and sufficient validity for human joint angles, with good usability and satisfaction.

Objective To determine the effects of repetitive peripheral magnetic stimulation in a patient with chronic stroke. Design Case report. Patients A man in his 70s presented with left hemiplegia secondary to cerebral hemorrhage. Methods An AB design was used: phase A (sham stimulation) and phase B (active stimulation). Magnetic stimulation was applied using a peripheral magnetic stimulator (Pathleader™, IFG, Sendai, Japan). Outcomes were assessed at four points: before the intervention, after phase A, after phase B, and at follow-up (3 weeks after phase B) using the Modified Ashworth Scale, range of motion, Fugl-Meyer Assessment, Simple Test for Evaluating Hand Function, and Canadian Occupational Performance Measures. Results The Modified Ashworth Scale score for the wrist extensor remained unchanged in phase A but improved after phase B and was sustained at follow-up. The range of motion showed no change. The Fugl-Meyer Assessment scores were 40, 41, 44, and 45, respectively, and the Simple Test for Evaluating Hand Function scores were 1, 4, 3, and 5, respectively, at the four time points. One Canadian Occupational Performance Measure item improved after phase B and remained stable. Conclusion In patients with chronic stroke and severe hemiplegia, repetitive peripheral magnetic stimulation may be effective in reducing spasticity and improving motor function.

Objective: To demonstrate the long-term efficacy of repeated botulinum toxin A injections into the same muscles for ameliorating lower limb spasticity and gait function.Design: Single-case studyPatient: A 36-year-old woman with right cerebral haemorrhage received her first botulinum toxin A injection 1,296 days after onset. The patient underwent 30 treatments over 12 years after the first injection to improve upper and lower limb spasticity and abnormal gait patterns. The mean duration between injections was 147 days.Methods: The Modified Ashworth Scale, passive range of motion, gait velocity, and degree of abnormal gait patterns during treadmill gait were evaluated pre-injection and at 2, 6, and 12 weeks after every injection.Results: The follow-up period showed no injection-related adverse events. Comfortable overground gait velocity gradually improved over 30 injections. The Modified Ashworth Scale and passive range of motion improved after each injection. Pre-injection values of the degree of pes varus, circumduction, hip hiking, and knee extensor thrust improved gradually. However, the degree of contralateral vaulting, excessive lateral shift of the trunk, and insufficient knee flexion did not improve after 30 injections.Conclusion: Repeated botulinum toxin A injections effectively improve abnormal gait patterns, even when a single injection cannot change these values.

OBJECTIVES: Falls can occur daily in stroke patients and appropriate independence assessments for fall prevention are required. Although previous studies evaluated the short physical performance battery (SPPB) in stroke patients, the relationship between SPPB and fall prediction and walking independence remains unclear. Therefore, we aimed to verify whether SPPB is a predictor of walking independence. MATERIALS AND METHODS: The present study included 105 hemiplegic stroke patients who were admitted to the rehabilitation ward and gave consent to participate. Cross-sectional physical function and functional independence measure cognitive (FIM-C) evaluation were conducted in hemiplegic stroke patients. Logistic regression analysis using the increasing variable method (likelihood ratio) was performed to extract factors for walking independence. Cutoff values were calculated for the extracted items using the receiver operating-characteristic (ROC) curve. RESULTS: Among 86 participants included in the final analysis, 36 were independent walkers and 50 were dependent walkers. In the logistic regression analysis, SPPB and FIM-C were extracted as factors for walking independence. The cutoff value was 7 [area under the curve (AUC), 0.94; sensitivity, 0.83; specificity, 0.73)] for SPPB and 32 (AUC, 0.83; sensitivity, 0.69; specificity, 0.57) for FIM-C in ROC analysis CONCLUSIONS: SPPB and FIM-C were extracted as factors for walking independence. Although SPPB alone cannot determine independent walking, combined assessment of SPPB with cognitive function may enable more accurate determination of walking independence.

BACKGROUND: Spasticity is defined as a velocity-dependent increase in tonic stretch reflexes and is manually assessed in clinical practice. However, the best method for the clinical assessment of spasticity has not been objectively described. This study analyzed the clinical procedure to assess spasticity of the elbow joint using an electrogoniometer and investigated the appropriate velocity required to elicit a spastic response and the influence of velocity on the kinematic response pattern. METHODS: This study included eight healthy individuals and 15 patients with spasticity who scored 1 or 1+ on the modified Ashworth Scale (MAS). Examiners were instructed to manually assess spasticity twice at two different velocities (slow and fast velocity conditions). During the assessment, velocity, deceleration value, and angle [described as the % range of motion (%ROM)] at the moment of resistance were measured using an electrogoniometer. Differences between the slow and fast conditions were evaluated. In addition, variations among the fast condition such as the responses against passive elbow extension at <200, 200-300, 300-400, 400°/s velocities were compared between the MAS 1+, MAS 1, and control groups. RESULTS: Significant differences were observed in the angular deceleration value and %ROM in the fast velocity condition (417 ± 80°/s) between patients and healthy individuals, but there was no difference in the slow velocity condition (103 ± 29°/s). In addition, the deceleration values were significantly different between the MAS 1 and MAS 1+ groups in velocity conditions faster than 300°/s. In contrast, the value of %ROM plateaued when the velocity was faster than 200°/s. CONCLUSION: The velocity of the passive motion had a significant effect on the response pattern of the elbow joint. The velocity-response pattern differed between deceleration and the angle at which the catch occurred; the value of deceleration value for passive motion was highly dependent on the velocity, while the %ROM was relatively stable above a certain velocity threshold. These results provide clues for accurate assessment of spasticity in clinical practice.

Background: Despite recent developments in the methodology for measuring spasticity, the discriminative capacity of clinically diagnosed spasticity has not been well established. This study aimed to develop a simple device for measuring velocity-dependent spasticity with improved discriminative capacity based on an analysis of clinical maneuver and to examine its reliability and validity. Methods: This study consisted of three experiments. First, to determine the appropriate motion of a mechanical device for the measurement of velocity-dependent spasticity, the movement pattern and the angular velocity used by clinicians to evaluate velocity-dependent spasticity were investigated. Analysis of the procedures performed by six physical therapists to evaluate spasticity were conducted using an electrogoniometer. Second, a device for measuring the resistance force against ankle dorsiflexion was developed based on the results of the first experiment. Additionally, preliminary testing of validity, as compared to that of the Modified Ashworth Scale (MAS), was conducted on 17 healthy participants and 10 patients who had stroke with spasticity. Third, the reliability of the measurement and the concurrent validity of mechanical measurement in the best ankle velocity setting were further tested in a larger sample comprising 24 healthy participants and 32 patients with stroke. Results: The average angular velocity used by physical therapists to assess spasticity was 268 ± 77°/s. A device that enabled the measurement of resistance force at velocities of 300°/s, 150°/s, 100°/s, and 5°/s was developed. In the measurement, an angular velocity of 300°/s was found to best distinguish patients with spasticity (MAS of 1+ and 2) from healthy individuals. A measurement of 300°/s in the larger sample differentiated the control group from the MAS 1, 1+, and 2 subgroups (p < 0.01), as well as the MAS 1 and 2 subgroups (p < 0.05). No fixed or proportional bias was observed in repeated measurements. Conclusion: A simple mechanical measurement methodology was developed based on the analysis of the clinical maneuver for measuring spasticity and was shown to be valid in differentiating the existence and extent of spasticity. This study suggest possible requirements to improve the quality of the mechanical measurement of spasticity.